NLRP3 and cancer: Although clinical investigations of single NLRP3 inhibitors in cancer therapy remain limited, a phase I/ II trial (NCT04971499) is currently underway to evaluate Dapansutrile combination with Pembrolizumab in patients with PD-1-resistant advanced melanoma[87].